Lineagen | GenomeWeb

Lineagen

NEW YORK (GenomeWeb) – Provo, Utah-based Tute Genomics said today that Patients Know Best — a developer of an online medical records system — has selected its cloud-based software for genome analysis and interpretation.

NEW YORK (GenomeWeb) − Genetic testing firm Lineagen this year plans to launch a sequencing-based diagnostic test for autism spectrum disorder (ASD), developmental delay, and other childhood developmental disorders that will complement its existing microarray-based test.

NEW YORK (GenomeWeb) – Tute Genomics announced that it will provide next-generation sequencing analytics for a molecular diagnostic test being developed by Lineagen for developmental delay, autism spectrum disorders, and other disorders of childhood development.

NEW YORK (GenomeWeb News) – Lineagen today announced it completed a Series C financing round that raised $3.5 million.

Companies that sell or are developing microarray-based tests for early stage autism diagnosis will soon face off against a competitor with a next-generation sequencing-based offering.

NEW YORK (GenomeWeb News) – Researchers have uncovered about two dozen novel copy-number variants strongly linked to autism-spectrum disorders, while also confirming the association of a furth

Lineagen has updated its chromosomal microarray testing service to include new variants associated with autism spectrum disorders.

Researchers who set out to compare the ability of SNP and comparative genomic hybridization microarray platforms to detect copy number variation in autusm spectrum disorder managed to identify 16 genes that hadn't been associated with ASD before.

The Center for Autism and Related Disorders, a provider of early intensive behavioral intervention for individuals with autism spectrum disorder, will now offer Lineagen's FirstStepDx test as a service to CARD patients and their families.

NEW YORK (GenomeWeb News) – The Center for Autism and Related Disorders and molecular diagnostics firm Lineagen today announced a partnership to offer the FirstStep genetic test to patients.

Pages

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.